This is a routine tax-motivated sale tied to RSU vesting under a 10b5-1 plan. No material insider signal. Monitor for any unplanned insider sales ahead of upcoming catalysts (e.g., clinical trial readouts).
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $38.06entry
- T+1 · 2mo ago −1.34%α −0.90% · $37.55
- T+5 · 8w ago −7.51%α −9.63% · $35.20
- T+20 · 5w ago −21.12%α −23.85% · $30.02
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Berndt Modig filed a Form 144 to sell 2,291 common shares (approx. $87K) on September 14, 2026. The shares were acquired upon vesting of restricted stock units on September 11-12, 2026. This is a small, routine sale by a director to cover tax obligations from RSU vesting, not a discretionary insider sale.
Key Facts
- Director Berndt Modig filed Form 144 to sell 2,291 shares of Pharvaris N.V. common stock.
- Estimated sale value: approximately $87,104 (based on ~$38.02/share).
- Shares were acquired upon vesting of restricted stock units on September 11-12, 2026.
- The sale is part of a pre-arranged 10b5-1 plan, with prior sales in June, July, and August 2026 of similar size.
- The filing represents intent to sell; the actual sale may not occur.
Financial Impact
~$87,000 sale by a director, representing a tiny fraction of the $2.6B market cap.
Risk Factors
- Form 144 is only an intent to sell; the actual sale may not execute.
- If the stock declines, the insider may choose not to sell at the lower price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-009440 |
| Document: 0001950047-26-009440-index.html | 0001950047-26-009440 |
| Document: 0001950047-26-009440.txt | 0001950047-26-009440 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers